29:
496:
Ghiringhelli, François; Doucet, Ludovic; Barre, Patricia; Pichon, Eric; Ponce Aix, Santiago; Juan-Vidal, Oscar; Carcereny, Enric; Sethi, Tariq; Lindmark, Bertil; MacKinnon, Alison; Aslanis, Vassilios; Rajiwate, Zahir; Basse, Linda (1 June 2022). "GALLANT-1: Galectin-3 (Gal-3) inhibitor GB1211 plus
411:
Aslanis, Vassilios; Slack, Robert J.; MacKinnon, Alison C.; McClinton, Catherine; Tantawi, Susan; Gravelle, Lise; Nilsson, Ulf J.; Leffler, Hakon; Brooks, Ashley; Khindri, Sanjeev K.; Marshall, Richard P.; Pedersen, Anders; Schambye, Hans; Zetterberg, Fredrik (March 2023).
314:
571:
532:
Mabbitt, Joseph; Roper, James A.; Slack, Robert John (1 June 2022). "Resistance to anti-PD-1/anti-PD-L1: GB1211 reverses galectin-3 induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1".
356:
InChI=1S/C19H16BrF3N4O4S/c20-9-3-10(5-24-4-9)32-19-18(30)16(17(29)14(7-28)31-19)27-6-13(25-26-27)8-1-11(21)15(23)12(22)2-8/h1-6,14,16-19,28-30H,7H2/t14-,16+,17+,18-,19-/m1/s1
328:
471:
414:"Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants"
566:
348:
78:
54:
180:
149:
497:
atezolizumab (atezo) in patients with non–small cell lung cancer (NSCLC)—A randomized, double-blind trial".
229:
581:
140:
576:
391:
596:
591:
586:
514:
169:
453:
435:
542:
506:
443:
425:
245:
189:
383:
510:
448:
413:
546:
129:
560:
518:
430:
379:
290:
160:
439:
387:
20:
457:
28:
115:
220:
106:)-2-(5-Bromopyridin-3-yl)sulfanyl-6-(hydroxymethyl)-4-oxane-3,5-diol
386:, which is testing the molecule to see if it reduces decompensated
209:
572:
Experimental drugs developed for non-alcoholic fatty liver disease
313:
304:
200:
336:
C1=C(C=C(C(=C1F)F)F)C2=CN(N=N2)3((O(3O)SC4=CC(=CN=C4)Br)CO)O
472:"New Agent Shows Promise in Decompensated Cirrhosis"
302:
289:
244:
239:
219:
199:
179:
159:
148:
139:
114:
69:
53:
48:
40:
35:
378:) is the first small-molecule, orally delivered
128:
382:inhibitor to be discovered. It is developed by
8:
19:
168:
27:
447:
429:
188:
403:
353:
333:
83:
18:
228:
7:
511:10.1200/JCO.2022.40.16_suppl.TPS9152
418:Cancer Chemotherapy and Pharmacology
208:
119:
14:
547:10.1200/JCO.2022.40.16_suppl.2607
271:
265:
256:
361:Key:FNCLKJPMEFPXOR-QFACEVIFSA-N
262:
394:(a type of anti-cancer drug).
283:
277:
250:
1:
535:Journal of Clinical Oncology
499:Journal of Clinical Oncology
613:
431:10.1007/s00280-023-04513-y
240:Chemical and physical data
567:Experimental cancer drugs
344:
324:
74:
26:
476:www.gastroendonews.com
505:(16_suppl): TPS9152.
392:checkpoint inhibitors
23:
541:(16_suppl): 2607.
390:and resistance to
369:
368:
315:Interactive image
16:Chemical compound
604:
551:
550:
529:
523:
522:
493:
487:
486:
484:
482:
468:
462:
461:
451:
433:
408:
317:
297:
285:
279:
273:
267:
264:
258:
252:
232:
212:
192:
172:
152:
132:
122:
121:
31:
24:
22:
612:
611:
607:
606:
605:
603:
602:
601:
557:
556:
555:
554:
531:
530:
526:
495:
494:
490:
480:
478:
470:
469:
465:
410:
409:
405:
400:
384:Galecto Biotech
365:
362:
357:
352:
351:
340:
337:
332:
331:
320:
295:
282:
276:
270:
261:
255:
235:
215:
195:
175:
155:
135:
118:
110:
107:
82:
81:
65:
62:Investigational
17:
12:
11:
5:
610:
608:
600:
599:
594:
589:
584:
579:
574:
569:
559:
558:
553:
552:
524:
488:
463:
424:(3): 267–280.
402:
401:
399:
396:
367:
366:
364:
363:
360:
358:
355:
347:
346:
345:
342:
341:
339:
338:
335:
327:
326:
325:
322:
321:
319:
318:
310:
308:
300:
299:
293:
287:
286:
280:
274:
268:
259:
253:
248:
242:
241:
237:
236:
234:
233:
225:
223:
217:
216:
214:
213:
205:
203:
197:
196:
194:
193:
185:
183:
177:
176:
174:
173:
165:
163:
157:
156:
154:
153:
145:
143:
137:
136:
134:
133:
125:
123:
112:
111:
109:
108:
85:
77:
76:
75:
72:
71:
67:
66:
64:
63:
59:
57:
51:
50:
46:
45:
42:
38:
37:
33:
32:
15:
13:
10:
9:
6:
4:
3:
2:
609:
598:
595:
593:
590:
588:
585:
583:
580:
578:
575:
573:
570:
568:
565:
564:
562:
548:
544:
540:
536:
528:
525:
520:
516:
512:
508:
504:
500:
492:
489:
477:
473:
467:
464:
459:
455:
450:
445:
441:
437:
432:
427:
423:
419:
415:
407:
404:
397:
395:
393:
389:
385:
381:
377:
373:
359:
354:
350:
343:
334:
330:
323:
316:
312:
311:
309:
306:
301:
294:
292:
288:
249:
247:
243:
238:
231:
230:ChEMBL5182222
227:
226:
224:
222:
218:
211:
207:
206:
204:
202:
198:
191:
187:
186:
184:
182:
178:
171:
167:
166:
164:
162:
158:
151:
147:
146:
144:
142:
138:
131:
127:
126:
124:
117:
113:
105:
101:
97:
93:
89:
84:
80:
73:
68:
61:
60:
58:
56:
52:
47:
43:
39:
36:Clinical data
34:
30:
25:
582:Fluoroarenes
538:
534:
527:
502:
498:
491:
479:. Retrieved
475:
466:
421:
417:
406:
375:
371:
370:
103:
99:
95:
91:
87:
55:Legal status
49:Legal status
577:Bromoarenes
372:Selvigaltin
298: g·mol
70:Identifiers
41:Other names
21:Selvigaltin
597:Thioethers
561:Categories
481:3 December
398:References
380:galectin-3
303:3D model (
291:Molar mass
190:94EN2E6BLW
161:ChemSpider
141:IUPHAR/BPS
79:IUPAC name
592:Pyridines
587:Triazoles
519:249450443
440:1432-0843
388:cirrhosis
170:115010772
130:122443488
458:36914828
449:10010643
246:Formula
116:PubChem
517:
456:
446:
438:
376:GB1211
329:SMILES
296:533.32
221:ChEMBL
210:D12763
44:GB1211
515:S2CID
349:InChI
305:JSmol
150:11202
483:2023
454:PMID
436:ISSN
201:KEGG
181:UNII
543:doi
507:doi
444:PMC
426:doi
120:CID
563::
539:40
537:.
513:.
503:40
501:.
474:.
452:.
442:.
434:.
422:91
420:.
416:.
263:Br
260:16
254:19
102:,6
98:,5
94:,4
90:,3
86:(2
549:.
545::
521:.
509::
485:.
460:.
428::
374:(
307:)
284:S
281:4
278:O
275:4
272:N
269:3
266:F
257:H
251:C
104:R
100:R
96:S
92:R
88:R
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
